Baird Financial Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Baird Financial Group’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,275	Closed	-$225K	–	1696
2020 Q4	$225K	Sell	2,275 -80	-3%	-$9.78K	﹤0.01%	1471
2020 Q3	$334K	Buy	2,355 +330	+16%	+$55K	﹤0.01%	1268
2020 Q2	$400K	Buy	2,025 +270	+15%	+$55.9K	﹤0.01%	1206
2020 Q1	$344K	Hold	1,755	–	–	﹤0.01%	1172
2019 Q4	$363K	Buy	1,755 +15	+0.9%	+$2.77K	﹤0.01%	1266
2019 Q3	$266K	Buy	1,740 +15	+0.9%	+$2.46K	﹤0.01%	1357
2019 Q2	$222K	Hold	1,725	–	–	﹤0.01%	1439
2019 Q1	$203K	Buy	+1,725	New	+$174K	﹤0.01%	1241

Other funds holding LKFT

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baird Financial Group's LKFT Position: Q1 2021 in Review

Baird Financial Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2021, closing a stake of 2,275 shares — an estimated $225K sold.

Baird Financial Group first reported a position in LKFT in Q1 2019 and held it in 8 quarters. The position peaked at $400K in Q2 2020. 131 funds tracked by Wall St. Rank hold LKFT as of Q1 2021.

Baird Financial Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2021 after selling out during the quarter.
Baird Financial Group sold 2,275 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2021, an estimated $225K.
Baird Financial Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2019 and held it in 8 quarters.
Baird Financial Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $400K in Q2 2020.
131 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2021.

Based on Baird Financial Group's 13F filing for Q1 2021, filed 13 May 2021.